<DOC>
	<DOC>NCT01615978</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to assess the safety after multiple s.c. (subcutaneously) doses of liraglutide in Japanese subjects with type 2 diabetes.</brief_summary>
	<brief_title>Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Duration of diabetes for more than 12 weeks Subjects currently on diet therapy (OHAna√Øve) or treated with OHA (oral hypoglycaemic agent) monotherapy for more than 12 weeks HbA1c (Glycated haemoglobin A1c) between 6.09.0 %, both inclusive Body Mass Index (BMI): 18.530.0 kg/m^2 Recurrent severe hypoglycaemia Proliferative retinopathy or maculopathy requiring acute treatment Impaired hepatic function Impaired renal function Cardiac problems Uncontrolled treated/untreated hypertension Current treatment with insulin preparations or TZDs (thiazolidinediones) Current treatment or expected at the screening to start treatment with systemic corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>